多西他赛联合奈达铂方案治疗晚期食管癌的临床观察

Clinical observation of docetaxel combined with nedaplatin in the treatment of advanced esophageal cancer

目的观察多西他赛联合奈达铂方案治疗晚期食管癌的近期疗效和毒副反应。方法69例晚期食管鳞状细胞癌患者随机分为2组：观察组35例，多西他赛75 mg/m2静脉滴注，第1天，奈达铂100 mg/m2静脉滴注，第1天；对照组34例，多西他赛75 mg/m2静脉滴注，第1天，顺铂75 mg/m2静脉滴注，第1天；每3周1个周期，至少完成2个周期。结果2组的总有效率相比，差异不具有统计学意义。治疗组Ⅲ～Ⅳ度毒性反应主要是白细胞及血小板减少，对照组Ⅲ～Ⅳ度毒性反应主要是恶心呕吐、食欲不振。结论在晚期食管癌中，多西他赛联合奈达铂方案与多西他赛联合顺铂方案疗效相近,但在毒副反应方面，多西他赛联合奈达铂方案耐受性良好，更具有优势。

Objective To observe the efficacy and toxicity of docmaxel combined with nedaplatin in the treatment of advanced esophageal cancer. Methods Sixty-nine patients with advanced esophageal squamous cell carcinoma were randomly divided into 2 groups. The observation group （n = 35） received docetaxel 75 mg/m; intravenous infusion on day 1, and nedaplatin 100 mg/ m2 intravenous infusion on day 1. The control group （n = 34） received docetaxel 75 mg/m2 intravenous infusion on day 1, and cisplatin 75 mg/m^2 intravenously on day 1. Every three weeks was taken as one cycle, and patients completed at least two cycles. Results The difference of efficiency was not statistically significant in the two groups. The main toxicity of grade Ⅲ～Ⅳ in the treatment group was leukopenia and thrombocytopenia. The main toxicity of grade Ⅲ～Ⅳ in the control group were nausea, vomiting and loss of appetite. Conclusion In advanced esophageal cancer, there is similar efficacy between the docetaxel combined with nedaplatin scheme and docetaxel combined with cisplatin scheme. But in terms of toxicity, docetaxel combined the nedaplatin program is well tolerated. The program has more advantages.